Search

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Session information—March 13, 2025

Topic'Primary Immunodeficiencies in Pediatric Hematooncology Practice. '

Speaker detailsCamilla Visconti (speaker)Dr Camilla Visconti is a final-year fellow in the Pediatric Immunology and BMT Unit at San Raffaele Hospital in Milan, where she manages children with inborn errors of immunity.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Guidelines Committee call for interest

The aim of the Guidelines Committee is to promote and support the creation and adoption of guidelines for diagnosis and treatment of hematologic diseases.

Read more

EHA-SRH-SHTRM Balkan Hematology Tutorial 2023

EHA is joining forces with the Societatea Românã de Hematologie (SRH) and Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova (SHTRM) to organize the EHA-SRH-SHRTM Balkan Hematology Tutorial.

Read more